Notícias e Atividades da Turn Therapeutics

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Turn Therapeutics

• Bradley Burnam, Chief Executive Officer and Founder
• Andrew Gengos, Board Director
• Kent Kester, Board Director

Recentes movimentos de executivos em Turn Therapeutics

• Stephen Hahn, ingressou na Companhia como Executive Clinical and Regulatory Lead  (Notícia publicada em 18 de maio de 2026).
• Martin Dewhurst, ingressou na Companhia como Board Member  (Notícia publicada em 9 de janeiro de 2026).
• Andrew Scott, ingressou na Companhia como Vice President of Corporate Communications  (Notícia publicada em 5 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Turn Therapeutics.

Turn Therapeutics possui 3.679 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Kaiser Permanente (Estados Unidos) e HCA (Estados Unidos).

Popular M&A news in Saúde

• Warburg Pincus adquiriu Integrace (publicado em 17 de julho de 2026).
• Neko Health acaba de anunciar uma arrecadação de fundos de 700 milhões de dólares. (publicado em 16 de julho de 2026).
• IKS Health adquiriu TruBridge (publicado em 10 de julho de 2026).

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Jagdeep Bijwadia - Experience Chief Medical Officer Chief Medical Officer da Happy Health
• Amy Brayford - Executive Vice President, Chief Human Resource Officer and Chief of Staff da Geisinger Health

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de Turn Therapeutics

• Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Mon, 07/06/2026 - 16:01
• Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Tue, 07/07/2026 - 08:05
• News Releases - Turn Therapeutics
• News Releases - Turn Therapeutics
• Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Mon, 06/01/2026 - 08:30
• Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - Wed, 05/27/2026 - 08:05
• Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - Tue, 05/19/2026 - 08:01
• Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Mon, 05/18/2026 - 08:05
• Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Mon, 05/11/2026 - 16:05
• Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Tue, 03/31/2026 - 16:05
• View more press releases Close

Redes sociais sobre Turn Therapeutics

• Turn Therapeutics na Wikipedia, Google News e Yahoo Finance
• Turn Therapeutics na LinkedIn, X (Twitter) e YouTube